Free Trial
Ends Tomorrow! Last Chance to Get MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion

Needham & Company LLC's Rating of Ocular Therapeutix on 10/19/2026

On October 19, 2026, Needham & Company LLC updated its outlook on Ocular Therapeutix (NASDAQ:OCUL) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Needham & Company LLC

DateCompanyAction
10/29/2026
Align Technology, Inc. stock logo
ALGN
Align Technology
Reiterated Rating
10/29/2026
eBay Inc. stock logo
EBAY
eBay
Boost Price Target
10/29/2026
Scorpio Tankers Inc. stock logo
STNG
Scorpio Tankers
Set Price Target
10/29/2026
Aurora Innovation, Inc. stock logo
AUR
Aurora Innovation
Lower Price Target
10/29/2026
KLA Corporation stock logo
KLAC
KLA
Reiterated Rating
10/29/2026
Q2 Holdings, Inc. stock logo
QTWO
Q2
Boost Price Target
More Ratings From Needham & Company LLC